

**Amendments to the Claims:**

1. (Currently Amended) A protein composed of SEQ ID No. 1 ~~or SEQ ID No. 2~~ characterized by having a nature to interact with proteasome.
2. (Withdrawn) A protein composed of SEQ ID No. 1 or SEQ ID No. 2 characterized by having a nature to interact with a polyubiquitin chain.
3. (Withdrawn) A therapeutic agent for disuse muscular atrophy characterized in that an expression or a function of a protein composed of SEQ ID No. 1 or SEQ ID No. 2 is inhibited.
4. (Withdrawn) A therapeutic agent for disuse muscular atrophy characterized in that an expression or a function of a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and proteasome is inhibited.
5. (Withdrawn) A therapeutic agent for disuse muscular atrophy characterized in that an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and a polyubiquitin chain is inhibited.
6. (Currently Amended) A method of producing a therapeutic agent for disuse muscular atrophy comprising the step of ~~Use of an interaction between~~ interacting a protein composed of SEQ ID No. 1 ~~or SEQ ID No. 2~~ and proteasome ~~for producing a therapeutic agent for disuse muscular atrophy.~~
7. (Withdrawn) A method for screening therapeutic agents for disuse muscular atrophy characterized by utilizing an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and proteasome.

8. (Withdrawn) A marker for disease diagnosis for disuse muscular atrophy characterized by utilizing an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and proteasome.
9. (Withdrawn) A method for evaluating the risk of onset of disuse muscular atrophy characterized by utilizing an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and proteasome.
10. (Withdrawn) Use of an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and a polyubiquitin chain for producing a therapeutic agent for disuse muscular atrophy.
11. (Withdrawn) A method for screening therapeutic agents for disuse muscular atrophy characterized by utilizing an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and a polyubiquitin chain.
12. (Withdrawn) A marker for disease diagnosis for disuse muscular atrophy characterized by utilizing an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and a polyubiquitin chain.
13. (Withdrawn) A method for evaluating the risk of onset of disuse muscular atrophy characterized by utilizing an interaction between a protein composed of SEQ ID No. 1 or SEQ ID No. 2 and a polyubiquitin chain.
14. (New). A protein composed of SEQ ID No. 1 characterized by having a nature to interact with at least one of the group consisting of proteasome and a polyubiquitin chain.
15. (New) The protein defined in claim 14 wherein the nature of interaction is an inhibition of an expression or function of said protein composed of SEQ ID No. 1.

16. (New) A method of producing a therapeutic agent for disuse muscular atrophy comprising the step of interacting said protein defined in claim 14 with one of the group consisting of proteasome and a polyubiquitin chain.
17. (New) A method of producing a marker for disuse muscular atrophy comprising the step of interacting said protein defined in claim 14 with one of the group consisting of proteasome and a polyubiquitin chain.
18. (New) A method for disease diagnosis for disuse muscular atrophy comprising the step of interacting said protein defined in claim 14 with one of the group consisting of proteasome and a polyubiquitin chain.
19. (New) A method for screening therapeutic agents for disuse muscular atrophy comprising the step of interacting said protein defined in claim 14 with one of the group consisting of proteasome and a polyubiquitin chain.
20. (New) A method for evaluating the risk of the onset of disuse muscular atrophy comprising the step of interacting said protein defined in claim 14 with one of the group consisting of proteasome and a polyubiquitin chain.